Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

We have recently demonstrated that the exopolysaccharides (EPSs) produced by a plant-derived lactic acid bacterium, <i>Lactobacillus paracasei</i> IJH-SONE68, prevent and ameliorate allergic reaction on contact in dermatitis model mice. In the present study, we conducted a clinical trial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masafumi Noda, Keishi Kanno, Narandalai Danshiitsoodol, Fumiko Higashikawa, Masanori Sugiyama
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	<i>Lactobacillus paracasei</i> chronic allergy clinical trial plant-derived lactic acid bacterium anti-inflammation Nutrition. Foods and food supply TX341-641
Acceso en línea:	https://doaj.org/article/1e957094058d44a9b3ce22edc065e865
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e957094058d44a9b3ce22edc065e865
record_format	dspace
spelling	oai:doaj.org-article:1e957094058d44a9b3ce22edc065e8652021-11-25T18:36:10ZPlant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial10.3390/nu131140222072-6643https://doaj.org/article/1e957094058d44a9b3ce22edc065e8652021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6643/13/11/4022https://doaj.org/toc/2072-6643We have recently demonstrated that the exopolysaccharides (EPSs) produced by a plant-derived lactic acid bacterium, <i>Lactobacillus paracasei</i> IJH-SONE68, prevent and ameliorate allergic reaction on contact in dermatitis model mice. In the present study, we conducted a clinical trial using a capsule containing spray-dried powder from pineapple juice broth fermented with the LAB strain as an experimental diet. The clinical trial was conducted as a double-blind and placebo-controlled randomized comparative study from May 2019 to July 2021. Males and females between the ages of 21 and 70 who experience chronic allergies participated in the study. Sixty subjects were instructed to orally take a capsule containing the IJH-SONE68 powder or placebo, every day for 12 weeks. After the clinical trial was over, the scores based on subjects’ self-assessment of allergic status were significantly improved in the intervention group, as compared with the placebo group. Some serum biochemicals associated with inflammation response were also significantly improved by intake of the experimental diet. In conclusion, the IJH-SONE68-derived EPS improves chronic allergy status in humans and is expected to decrease their inconvenience.Masafumi NodaKeishi KannoNarandalai DanshiitsoodolFumiko HigashikawaMasanori SugiyamaMDPI AGarticle<i>Lactobacillus paracasei</i>chronic allergyclinical trialplant-derived lactic acid bacteriumanti-inflammationNutrition. Foods and food supplyTX341-641ENNutrients, Vol 13, Iss 4022, p 4022 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	<i>Lactobacillus paracasei</i> chronic allergy clinical trial plant-derived lactic acid bacterium anti-inflammation Nutrition. Foods and food supply TX341-641
spellingShingle	<i>Lactobacillus paracasei</i> chronic allergy clinical trial plant-derived lactic acid bacterium anti-inflammation Nutrition. Foods and food supply TX341-641 Masafumi Noda Keishi Kanno Narandalai Danshiitsoodol Fumiko Higashikawa Masanori Sugiyama Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
description	We have recently demonstrated that the exopolysaccharides (EPSs) produced by a plant-derived lactic acid bacterium, <i>Lactobacillus paracasei</i> IJH-SONE68, prevent and ameliorate allergic reaction on contact in dermatitis model mice. In the present study, we conducted a clinical trial using a capsule containing spray-dried powder from pineapple juice broth fermented with the LAB strain as an experimental diet. The clinical trial was conducted as a double-blind and placebo-controlled randomized comparative study from May 2019 to July 2021. Males and females between the ages of 21 and 70 who experience chronic allergies participated in the study. Sixty subjects were instructed to orally take a capsule containing the IJH-SONE68 powder or placebo, every day for 12 weeks. After the clinical trial was over, the scores based on subjects’ self-assessment of allergic status were significantly improved in the intervention group, as compared with the placebo group. Some serum biochemicals associated with inflammation response were also significantly improved by intake of the experimental diet. In conclusion, the IJH-SONE68-derived EPS improves chronic allergy status in humans and is expected to decrease their inconvenience.
format	article
author	Masafumi Noda Keishi Kanno Narandalai Danshiitsoodol Fumiko Higashikawa Masanori Sugiyama
author_facet	Masafumi Noda Keishi Kanno Narandalai Danshiitsoodol Fumiko Higashikawa Masanori Sugiyama
author_sort	Masafumi Noda
title	Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_short	Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_full	Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_fullStr	Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_full_unstemmed	Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_sort	plant-derived <i>lactobacillus paracasei</i> ijh-sone68 improves chronic allergy status: a randomized, double-blind, placebo-controlled clinical trial
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1e957094058d44a9b3ce22edc065e865
work_keys_str_mv	AT masafuminoda plantderivedilactobacillusparacaseiiijhsone68improveschronicallergystatusarandomizeddoubleblindplacebocontrolledclinicaltrial AT keishikanno plantderivedilactobacillusparacaseiiijhsone68improveschronicallergystatusarandomizeddoubleblindplacebocontrolledclinicaltrial AT narandalaidanshiitsoodol plantderivedilactobacillusparacaseiiijhsone68improveschronicallergystatusarandomizeddoubleblindplacebocontrolledclinicaltrial AT fumikohigashikawa plantderivedilactobacillusparacaseiiijhsone68improveschronicallergystatusarandomizeddoubleblindplacebocontrolledclinicaltrial AT masanorisugiyama plantderivedilactobacillusparacaseiiijhsone68improveschronicallergystatusarandomizeddoubleblindplacebocontrolledclinicaltrial
_version_	1718410878983864320

Plant-Derived <i>Lactobacillus paracasei</i> IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Ejemplares similares